Last reviewed · How we verify
Biscolan (choline dehydrocholate)
Biscolan (generic name: choline dehydrocholate) is a drug. It is currently in unknown development.
Biscolan works by binding to a specific target, although the identity of this target is currently unknown.
Biscolan, also known as choline dehydrocholate, is a small molecule modality with unknown drug class and target. Its commercial status is unclear, and it is not known whether it is FDA approved or off-patent. The approved indications for Biscolan are also unknown. As a small molecule, Biscolan is likely to be administered orally, but its pharmacokinetic properties, including half-life and bioavailability, are not well-documented. Further research is needed to fully understand the safety and efficacy of Biscolan.
At a glance
| Generic name | choline dehydrocholate |
|---|---|
| Therapeutic area | Other |
| Phase | unknown |
Mechanism of action
Think of Biscolan like a key that fits into a lock. When it binds to its target, it can help to turn off or slow down certain processes in the body that are involved in a particular disease or condition. This can help to alleviate symptoms and improve quality of life for people taking the medication.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Biscolan CI brief — competitive landscape report
- Biscolan updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about Biscolan
What is Biscolan?
How does Biscolan work?
What is the generic name of Biscolan?
What development phase is Biscolan in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing